{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:39:29Z","timestamp":1792067969457,"version":"4.4.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study aims to evaluate clinical, biochemical, and histopathological determinants of disease severity and postoperative outcomes in parathyroid tumors and to assess whether a composite histology\u2013biomarker risk score provides an integrated framework to better characterize tumor behavior beyond conventional histological classification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective multicenter cohort study included patients with primary hyperparathyroidism caused by typical adenoma (TA), atypical parathyroid tumor (APT), or nonmetastatic parathyroid carcinoma (PC) diagnosed between 2000 and 2021 in three tertiary hospitals. Outcomes included preoperative parathyroid hormone (PTH) and calcium levels, postoperative hypocalcemia, and persistent hyperparathyroidism at 6 months. A composite unweighted risk score (range 0-5) was developed, assigning one point for each adverse feature: atypical\/malignant histology, loss of parafibromin, Ki-67 \u2265 3%, and positive galectin-3 or PGP9.5 expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 139 patients were analyzed (64.7% women; mean age 58.3 \u00b1 13.6 years), including 90 TA, 20 APT, and 29 PC. Preoperative PTH and calcium levels increased progressively with the risk score (P &amp;lt; .001). Postoperative hypocalcemia rising from 0% in score 0% to 53% in scores \u2265 4, while persistent hyperparathyroidism increased from 6% to 45% (P &amp;lt; .01). Each one-point increase in the score was associated with postoperative hypocalcemia (odds ratio [OR] = 2.00) and persistent hyperparathyroidism (OR = 1.87), independent of age, sex, chronic kidney disease, and surgical extent. Model discrimination was good (area under the curve [AUC] of an analysis using receiver operating characteristic [ROC] curves 0.78-0.81) with stable calibration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The composite histology\u2013biomarker risk score was linearly associated with biochemical severity and postoperative outcomes, offering a practical tool to refine risk stratification beyond histological classification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejendo\/lvaf240","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T13:13:51Z","timestamp":1763558031000},"page":"667-676","source":"Crossref","is-referenced-by-count":1,"title":["Integrating histology and biomarkers to predict clinical outcomes in parathyroid tumors: a multicenter study"],"prefix":"10.1093","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0951-5428","authenticated-orcid":false,"given":"Pablo","family":"Rodr\u00edguez de Vera G\u00f3mez","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Nutrition, Virgen Macarena University Hospital , Seville 41009 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Machuca Aguado","sequence":"additional","affiliation":[{"name":"Department of Pathology, Virgen Macarena University Hospital , Seville 41009 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Rodr\u00edguez-Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Virgen Macarena University Hospital , Seville 41009 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Guti\u00e9rrez Domingo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Virgen Macarena University Hospital , Seville 41009 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"S\u00e1nchez-Malo","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Jaen Hospital Complex , Jaen 23007 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Romo Remigio","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Jaen Hospital Complex , Jaen 23007 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Dolores","family":"Mart\u00edn Salvago","sequence":"additional","affiliation":[{"name":"Department of Pathology, Jaen Hospital Complex , Jaen 23007 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enriqueta","family":"Montijano Pozas","sequence":"additional","affiliation":[{"name":"Department of Pathology, Virgen del Roc\u00edo University Hospital , Seville 41013 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Mangas Cruz","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Virgen del Roc\u00edo University Hospital , Seville 41013 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1s","family":"Mart\u00edn-Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Virgen Macarena University Hospital , Seville 41009 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Idoate Gastearena","sequence":"additional","affiliation":[{"name":"Department of Pathology, Virgen Macarena University Hospital , Seville 41009 ,","place":["Spain"]},{"name":"Department of Pathology, Gregorio Mara\u00f1\u00f3n University Hospital , Madrid 28007 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"issue":"1","key":"2025120803463898800_lvaf240-B1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s12022-022-09709-1","article-title":"Overview of the 2022 WHO classification of parathyroid tumors","volume":"33","author":"Erickson","year":"2022","journal-title":"Endocr Pathol"},{"issue":"4","key":"2025120803463898800_lvaf240-B2","doi-asserted-by":"publisher","first-page":"BSR20181778","DOI":"10.1042\/BSR20181778","article-title":"Diagnostic and prognostic implications of parafibromin immunohistochemistry in parathyroid carcinoma","volume":"39","author":"Pyo","year":"2019","journal-title":"Biosci Rep"},{"issue":"2","key":"2025120803463898800_lvaf240-B3","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1677\/ERC-07-0021","article-title":"Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification","volume":"14","author":"Juhlin","year":"2007","journal-title":"Endocr Relat Cancer"},{"issue":"19","key":"2025120803463898800_lvaf240-B4","doi-asserted-by":"publisher","first-page":"6629","DOI":"10.1158\/1078-0432.CCR-04-0493","article-title":"Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma","volume":"10","author":"Tan","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2025120803463898800_lvaf240-B5","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1530\/EC-13-0046","article-title":"CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer","volume":"2","author":"Cetani","year":"2013","journal-title":"Endocr Connect"},{"key":"2025120803463898800_lvaf240-B6","doi-asserted-by":"publisher","first-page":"e2024514","DOI":"10.4322\/acr.2024.514","article-title":"Large atypical parathyroid tumor\u2014a diagnostic conundrum","volume":"14","author":"Mitra","year":"2024","journal-title":"Autops Case Rep"},{"issue":"7","key":"2025120803463898800_lvaf240-B7","doi-asserted-by":"publisher","first-page":"R441","DOI":"10.1530\/ERC-19-0135","article-title":"Atypical parathyroid adenomas: challenging lesions in the differential diagnosis of endocrine tumors","volume":"26","author":"Cetani","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"2025120803463898800_lvaf240-B8","doi-asserted-by":"publisher","first-page":"1027598","DOI":"10.3389\/fendo.2023.1027598","article-title":"Clinical and genetic analysis of atypical parathyroid adenoma compared with parathyroid carcinoma and benign lesions in a Chinese cohort","volume":"14","author":"Chen","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"2025120803463898800_lvaf240-B9","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.3390\/cancers17111783","article-title":"Diagnostic and surgical challenges in parathyroid neoplasia","volume":"17","author":"Simescu","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"10","key":"2025120803463898800_lvaf240-B10","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1097\/PAI.0000000000000378","article-title":"Parafibromin, APC, and MIB-1 are useful markers for distinguishing parathyroid carcinomas from adenomas","volume":"25","author":"Hosny Mohammed","year":"2017","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"4","key":"2025120803463898800_lvaf240-B11","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s12022-019-09592-3","article-title":"Using a novel diagnostic nomogram to differentiate malignant from benign parathyroid neoplasms","volume":"30","author":"Silva-Figueroa","year":"2019","journal-title":"Endocr Pathol"},{"issue":"3","key":"2025120803463898800_lvaf240-B12","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1007\/s12020-016-0997-3","article-title":"Diagnostic performance of parafibromin immunohistochemical staining for sporadic parathyroid carcinoma: a meta-analysis","volume":"54","author":"Hu","year":"2016","journal-title":"Endocrine"},{"issue":"4","key":"2025120803463898800_lvaf240-B13","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/cen.14161","article-title":"Prognostic role of parafibromin staining and CDC73 mutation: a systematic review and meta-analysis","volume":"92","author":"Zhu","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"2025120803463898800_lvaf240-B14","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1002\/jbmr.4665","article-title":"Epidemiology, pathophysiology, and genetics of primary hyperparathyroidism","volume":"37","author":"Minisola","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2025120803463898800_lvaf240-B15","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1007\/s12020-024-03687-6","article-title":"Significance of an IHC marker panel in diagnosing parathyroid carcinoma","volume":"84","author":"Hu","year":"2024","journal-title":"Endocrine"},{"issue":"2","key":"2025120803463898800_lvaf240-B16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s12022-018-9527-6","article-title":"Immunohistochemistry in diagnostic parathyroid pathology","volume":"29","author":"Erickson","year":"2018","journal-title":"Endocr Pathol"},{"issue":"4","key":"2025120803463898800_lvaf240-B17","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/ejendo\/lvae121","article-title":"Parathyroid carcinoma and atypical parathyroid tumor: analysis of an Italian database","volume":"191","author":"Marini","year":"2024","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2025120803463898800_lvaf240-B18","doi-asserted-by":"publisher","first-page":"P15","DOI":"10.1530\/EJE-19-0157","article-title":"Parafibromin-negative parathyroid tumors: clinical and molecular features","volume":"181","author":"Gill","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2025120803463898800_lvaf240-B19","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.humpath.2005.06.020","article-title":"Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases","volume":"36","author":"Bergero","year":"2005","journal-title":"Hum Pathol"},{"issue":"1","key":"2025120803463898800_lvaf240-B20","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s12022-024-09804-5","article-title":"Not all parafibromin deficiency relates to carcinoma: role of morphology","volume":"35","author":"Juhlin","year":"2024","journal-title":"Endocr Pathol"},{"issue":"12","key":"2025120803463898800_lvaf240-B21","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1245\/s10434-015-4672-3","article-title":"Parathyroid carcinoma: an update on treatment outcomes and prognostic factors from the national cancer data base (NCDB)","volume":"22","author":"Asare","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"2025120803463898800_lvaf240-B22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12957-023-02912-2","article-title":"Evaluation of factors predicting postoperative recurrence and metastasis of parathyroid cancer: a single-center study","volume":"21","author":"Ohkuwa","year":"2023","journal-title":"World J Surg Onc"},{"issue":"6","key":"2025120803463898800_lvaf240-B23","doi-asserted-by":"publisher","first-page":"e536","DOI":"10.1016\/j.surge.2021.01.011","article-title":"Parathyroid cancer: a systematic review of diagnostic biomarkers","volume":"19","author":"Davies","year":"2021","journal-title":"Surgeon"},{"key":"2025120803463898800_lvaf240-B24","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-19425-7","volume-title":"Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis","author":"Harrell","year":"2015","edition":"2nd ed"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvaf240\/65415294\/lvaf240.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/6\/667\/65415294\/lvaf240.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/6\/667\/65415294\/lvaf240.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T08:46:46Z","timestamp":1765183606000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/193\/6\/667\/8332110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvaf240","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,11,20]]}}}